ALN-SOD

RNA / oligonucleotide

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Amyotrophic Lateral Sclerosis
NCT06351592 · Regeneron Pharmaceuticals
2024-08-28 – 2032-03-21 · Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ALN-SOD: this drugPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication
Edaravone (Radicava ORS)ApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
Tofersen (Qalsody)ApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
UlefnersenPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
IbudilastPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
DazucorilantPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ALN-SOD to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2032 (1)
March 2032 (1)
Phase 1/2Amyotrophic Lateral SclerosisRecruiting
Est. primary completion 2032-03-21 · NCT06351592 · CT.gov ↗
What to watch

See the full readout calendar ↗